银屑病和银屑病关节炎。
Psoriasis and Psoriatic Arthritis.
作者信息
Cather Jennifer Clay, Young Melodie, Bergman Martin Jan
机构信息
Modern Dermatology and Modern Research Associates, Dallas, Texas.
Drexel University College of Medicine, Philadelphia, Pennsylvania; Taylor Hospital, Ridley Park, Pennsylvania.
出版信息
J Clin Aesthet Dermatol. 2017 Mar;10(3):S16-S25. Epub 2017 Mar 1.
Abstract
Psoriasis is a dynamic systemic disease that can have a profound affect on a patient's self-esteem. Fortunately, numerous therapeutic advances have been made over the last 10 years. In order to help patients manage their disease, healthcare providers should be aware of the modifiable risk factors that may exacerbate psoriasis. Additionally, exploring the impact the disease has on a patient and how it may change over their lifespan will help ensure appropriate therapies are used. Patients are unique so one medication will not fit all of our patients' needs. In this paper, the authors look at available treatment options for psoriasis and psoriatic arthritis. Educating psoriasis patients, in addition to collaborating with patients and other healthcare providers, may help initiate therapies that will result in patients living their lives to the fullest.
摘要
银屑病是一种动态的全身性疾病，会对患者的自尊产生深远影响。幸运的是，在过去10年里已经取得了许多治疗进展。为了帮助患者管理他们的疾病，医疗保健提供者应该了解可能加重银屑病的可改变风险因素。此外，探究该疾病对患者的影响以及它在患者一生中可能如何变化，将有助于确保使用适当的治疗方法。患者是独特的，所以一种药物并不适合所有患者的需求。在本文中，作者探讨了银屑病和银屑病关节炎的现有治疗选择。除了与患者和其他医疗保健提供者合作外，对银屑病患者进行教育可能有助于启动能让患者充分享受生活的治疗方法。
相似文献
1
Psoriasis and Psoriatic Arthritis.银屑病和银屑病关节炎。
J Clin Aesthet Dermatol. 2017 Mar;10(3):S16-S25. Epub 2017 Mar 1.
2
Impact of Disease Factors of Patients with Psoriasis and Psoriatic Arthritis on Biologic Therapy Switching: Real-World Evidence from the CorEvitas Psoriasis Registry.银屑病和银屑病关节炎患者的疾病因素对生物治疗转换的影响：来自CorEvitas银屑病登记处的真实世界证据
Dermatol Ther (Heidelb). 2024 Oct;14(10):2805-2825. doi: 10.1007/s13555-024-01258-1. Epub 2024 Sep 16.
3
Clinical monograph for drug formulary review: systemic agents for psoriasis/psoriatic arthritis.药物处方集评审临床专论：银屑病/银屑病关节炎的全身用药
J Manag Care Pharm. 2005 Jan-Feb;11(1):33-55. doi: 10.18553/jmcp.2005.11.1.33.
4
Experiences of Dermatologists and Patients Regarding Psoriasis and Its Connection to Psoriatic Arthritis in Saudi Arabia.沙特阿拉伯皮肤科医生和患者关于银屑病及其与银屑病关节炎关联的经历
Psoriasis (Auckl). 2024 Jan 18;14:11-22. doi: 10.2147/PTT.S427775. eCollection 2024.
5
Contemporary treatment patterns in plaque psoriasis and psoriatic arthritis.斑块状银屑病和银屑病关节炎的当代治疗模式
Postepy Dermatol Alergol. 2021 Feb;38(2):80-84. doi: 10.5114/ada.2019.91502. Epub 2020 Apr 9.
6
Prevalence of Musculoskeletal Symptoms in Patients with Psoriasis and Predictors Associated with the Development of Psoriatic Arthritis: Retrospective Analysis of a US Claims Database.银屑病患者肌肉骨骼症状的患病率及与银屑病关节炎发生相关的预测因素：美国索赔数据库的回顾性分析
Dermatol Ther (Heidelb). 2023 Nov;13(11):2635-2648. doi: 10.1007/s13555-023-01025-8. Epub 2023 Sep 19.
7
Physician perspectives in the management of psoriasis and psoriatic arthritis: results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis survey.银屑病和银屑病关节炎管理中的医生观点：基于人群的银屑病和银屑病关节炎多国评估调查结果
J Eur Acad Dermatol Venereol. 2015 Oct;29(10):2002-10. doi: 10.1111/jdv.13150. Epub 2015 Apr 16.
8
Patient Perspectives on Psoriatic Disease Burden: Results from the Global Psoriasis and Beyond Survey.患者对银屑病负担的看法：来自全球银屑病及其他疾病调查的结果。
Dermatology. 2023;239(4):621-634. doi: 10.1159/000528945. Epub 2023 Apr 19.
9
Impact of Psoriatic Disease on Quality of Life: Interim Results of a Global Survey.银屑病对生活质量的影响：一项全球调查的中期结果。
Dermatol Ther (Heidelb). 2022 Apr;12(4):1055-1064. doi: 10.1007/s13555-022-00695-0. Epub 2022 Mar 14.
10
Psoriasis and psoriatic arthritis treatment.银屑病和银屑病关节炎的治疗。
Am J Manag Care. 2016 Jun;22(8 Suppl):s225-37.
引用本文的文献
1
Guselkumab, a Novel Monoclonal Antibody Inhibitor of the p19 Subunit of IL-23, for Psoriatic Arthritis and Plaque Psoriasis: A Review of Its Mechanism, Use, and Clinical Effectiveness.古塞库单抗，一种新型白细胞介素-23 p19亚基单克隆抗体抑制剂，用于治疗银屑病关节炎和斑块状银屑病：其作用机制、用法及临床疗效综述
Cureus. 2023 Dec 31;15(12):e51405. doi: 10.7759/cureus.51405. eCollection 2023 Dec.
2
Translation, cultural adaptation and validation of the Somatic Symptom Scale-8 (SSS-8) for the Brazilian Portuguese language.躯体症状量表-8（SSS-8）的巴西葡萄牙语版翻译、文化调适和验证。
BMC Prim Care. 2022 Sep 5;23(1):222. doi: 10.1186/s12875-022-01836-2.
3
Dynamic Visual Representation of Clinical Efficacy of Ixekizumab in Psoriasis.司库奇尤单抗治疗银屑病临床疗效的动态视觉呈现
Dermatol Ther (Heidelb). 2021 Aug;11(4):1107-1118. doi: 10.1007/s13555-021-00548-2. Epub 2021 May 29.
4
Use of antidepressants and benzodiazepine-related hypnotics before and after initiation of TNF-α inhibitors or non-biological systemic treatment in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis.类风湿关节炎、银屑病关节炎或强直性脊柱炎患者在开始使用肿瘤坏死因子-α抑制剂或非生物系统性治疗之前及之后使用抗抑郁药和苯二氮䓬类相关催眠药的情况。
BMC Rheumatol. 2020 Feb 12;4:9. doi: 10.1186/s41927-019-0106-3. eCollection 2020.
5
Selective JAKinibs: Prospects in Inflammatory and Autoimmune Diseases.选择性 JAK 抑制剂：在炎症和自身免疫性疾病中的前景。
BioDrugs. 2019 Feb;33(1):15-32. doi: 10.1007/s40259-019-00333-w.
本文引用的文献
1
Patient-reported outcomes in cancer survivorship.癌症幸存者的患者报告结局
Acta Oncol. 2017 Feb;56(2):166-173. doi: 10.1080/0284186X.2016.1268265. Epub 2017 Jan 13.
2
Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders: A Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2 and -3).在依那西普无反应者中转换为司库奇尤单抗的疗效和安全性：来自两项中重度斑块状银屑病III期随机临床试验（UNCOVER-2和-3）的亚组分析
Am J Clin Dermatol. 2017 Apr;18(2):273-280. doi: 10.1007/s40257-016-0246-9.
3
Updates on Psoriasis and Cutaneous Oncology: Proceedings from the 2016 MauiDerm Meeting based on presentations by.银屑病与皮肤肿瘤学进展：基于2016年毛伊岛皮肤科学术会议演讲内容的会议记录
J Clin Aesthet Dermatol. 2016 Sep;9(9 Suppl 1):S5-S29. Epub 2016 Sep 1.
4
Secukinumab: A New Treatment Option for Psoriatic Arthritis.司库奇尤单抗：银屑病关节炎的一种新治疗选择。
Rheumatol Ther. 2016 Jun;3(1):5-29. doi: 10.1007/s40744-016-0031-5. Epub 2016 Apr 23.
5
Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1.司库奇尤单抗，一种白细胞介素-17A特异性单克隆抗体，用于治疗初治的活动性银屑病关节炎患者：III期试验SPIRIT-P1的24周随机、双盲、安慰剂对照及活性（阿达木单抗）对照阶段的结果
Ann Rheum Dis. 2017 Jan;76(1):79-87. doi: 10.1136/annrheumdis-2016-209709. Epub 2016 Aug 23.
6
Ustekinumab Treatment and Improvement of Physical Function and Health-Related Quality of Life in Patients With Psoriatic Arthritis.优特克单抗治疗对银屑病关节炎患者身体功能及健康相关生活质量的改善作用
Arthritis Care Res (Hoboken). 2016 Dec;68(12):1812-1822. doi: 10.1002/acr.23000. Epub 2016 Oct 21.
7
Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis.依奇珠单抗治疗中重度斑块状银屑病的 3 期临床试验。
N Engl J Med. 2016 Jul 28;375(4):345-56. doi: 10.1056/NEJMoa1512711. Epub 2016 Jun 8.
8
Assessment of Possible Drug Interactions in Patients with Psoriasis and Associated Comorbid Medical Conditions: An Observational Study.银屑病及相关合并症患者潜在药物相互作用的评估：一项观察性研究。
Rev Recent Clin Trials. 2016;11(2):128-34. doi: 10.2174/1574887111666160201122532.
9
Methotrexate Efficacy in the Tight Control in Psoriatic Arthritis Study.甲氨蝶呤在银屑病关节炎严格控制研究中的疗效
J Rheumatol. 2016 Feb;43(2):356-61. doi: 10.3899/jrheum.150614. Epub 2015 Dec 15.
10
Psychometric validation of the Psoriasis Symptom Diary using Phase III study data from patients with chronic plaque psoriasis.使用慢性斑块状银屑病患者的III期研究数据对银屑病症状日记进行心理测量学验证。
Int J Dermatol. 2016 Mar;55(3):e147-55. doi: 10.1111/ijd.13117. Epub 2015 Oct 30.
Zotero 插件